Legal Cannabis Product Sales Gain Momentum

Wednesday, August 9, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, August 9, 2017 /PRNewswire/ --

According to a research

report published by New Frontier Data, medical cannabis sales are forecast to grow to $5.3 billion in 2017, or accounting for 67% of total cannabis sales. By 2025, medical sales in currently legal states are forecast to
grow to $13.2 billion and at which point medical sales will account for 55% of all sales. In comparison, sales of cannabis products for recreational purposes in 2017 are forecast to reach $2.6 billion or rising to $10.9 billion by 2025. The state of California by itself is projected to encompass a major portion of the entire market. The report indicates that the state's legal industry is forecast to grow from $2.8 billion in 2017, to $5.6 billion in 2020. Global Payout, Inc. (OTC: GOHE), Marijuana Company of America, Inc. (OTC: MCOA), CV Sciences, Inc. (OTC: CVSI), MassRoots Inc. (OTC: MSRT), mCig, Inc. (OTC: MCIG).

"Cannabis stocks significantly outperformed major indexes in 2016, fueled by speculative investment based on anticipated expansion of new legal markets. In the run up to the election, stocks increased by 207.8% and continued to rise, even with an uncertain future under the new administration. While recent comments by the Trump administration did have an initial dampening effect on the market, we have seen continued growth relative to Q4 2016 whereby cannabis stocks are still outperforming other sectors," said Giadha Aguirre De Carcer, CEO of New Frontier Data.

Global Payout, Inc. (OTC: GOHE) announced on July 27th that Marijuana Company of America, Inc. (OTC: MCOA) has completed an investment of $250,000 into MoneyTrac Technology, Inc. ("MTT"), a subsidiary of Global Payout, Inc., in exchange for a 15% ownership interest.

MCOA made this investment to help establish and market MTT as an alternative banking solution for the cannabis industry. MoneyTrac's software has the ability to integrate and streamline electronic payment processing, such as E-Wallet and mobile applications, as well as manage and process prepaid cards, debit cards, and credit card payments.

As part of the terms of the investment, Donald Steinberg, CEO and President of MCOA, was appointed to the board of MTT this year where he is lending the invaluable experience he has acquired throughout his career in building alternative financial solution companies to the MTT executive management team.

"We are excited to help guide MTT through its developmental stages and are optimistic about the potential of MCOA's investment into this new project. This is another example of MCOA's strong strategic partnerships with emerging companies in our industry," Donald Steinberg said.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. Earlier in June the company announced that, it held its pre-IND meeting with the U.S. Food and Drug Administration (FDA) on June 15, 2017, to review its drug development plan for CVSI-007, the Company's patent-pending product for smokeless tobacco addiction therapy consisting of nicotine-polacrilex chewing gum in combination with synthetic cannabidiol (CBD). CV Sciences President and CEO Michael J. Mona, Jr. commented, "Our pre-IND meeting with the FDA was very constructive and provided the Company with a favorable development roadmap for this important combination drug candidate. We have immediately commenced preparation of our Investigational New Drug application (IND) to initiate human trials. Our New Drug Application will be under the 505(b)2 pathway using nicotine-polacrilex gum, an FDA-approved nicotine replacement therapy, as our referenced listed drug."

MassRoots Inc. (OTCQB: MSRT) on August 3rd announced that the point-of-sale and compliance software platform it is acquiring and is expected to fully close on August 5, 2017, previously known as Odava, has been re-branded as MassRoots Retail. MassRoots is now prioritizing resources towards its software solutions for licensed dispensaries and connecting its community of over 1,000,000 of the world's top cannabis enthusiasts with the best products and strains in regulated markets. "We believe Facebook is the undisputed leader in social networking and rather than trying to compete, we are focusing our efforts on better connecting our users with the best licensed dispensaries and products. Soon, users will also be able to login to MassRoots with their Facebook accounts," stated MassRoots CEO Isaac Dietrich.

mCig, Inc. (OTCQB: MCIG) a diversified company servicing the legal cannabis markets with innovative products, technologies, and services. Earlier in July mCig provided an update, revealing that the company looks to make an acquisition of existing cultivation, production and distribution licenses in California, Nevada, and other recreational states. In addition, the company has interest in acquiring proprietary cannabis oil extraction technologies and established leading brands that can help accelerate growth and expand the company's reach. The acquisition strategy is intended to strengthen the company's intellectual property and national presence, while further building the mCig portfolio and driving financial and shareholder value.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated four thousand dollars for financial news dissemination and pr services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: +1-877-601-1879


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store